The European Haemophilia Consortium / X
Jul 1, 2025, 18:13
5th EHC HTA Stakeholder Meeting: Driving Change for the Bleeding Disorders Community
The European Haemophilia Consortium recently shared a post on X:
”We had a meaningful day advocating for patients with bleeding disorders at the 5th HTA Stakeholder Meeting:
– Patients must be co-creators, not bystanders;
– Training is key–patient experts need the right tools;
– Metrics matter–patients should have a voice in what’s measured.”
At the 5th Health Technology Assessment-HTA Stakeholder Meeting, EHC made one thing clear: patients are not passive participants—they are partners in progress.
Here is what the day reinforced:
- HTA can’t afford to be a closed-door process. People living with bleeding disorders must be involved from the start—not as an afterthought, but as co-authors of the system that evaluates their care.
- What gets measured gets valued. Patients deserve a voice in defining what outcomes truly matter, beyond charts and cost curves.
Overall, this meeting was a reminder that HTA isn’t just about cost-effectiveness. It’s about people.
More on the news of bleeding disorders in Hemostasis Today.
-
Aug 18, 2025, 13:21Gehan Lotfy Khalifa and Colleagues Share a Egyptian Pediatric Guidelines for Childhood VTE
-
Aug 18, 2025, 09:45Mark Lewis: aPTT Pathway—What Activates What
-
Aug 18, 2025, 08:48William Aird: Physical Exam in Hit
-
Aug 17, 2025, 23:32Platelets Carry Tumor DNA! Powerful Potential for Liquid Biopsies and Precision Cancer Detection
-
Aug 17, 2025, 23:31European Heart Journal Highlights Emerging Heart Risk Factors: Climate Change, Infections, and Extreme Sports
-
Aug 18, 2025, 11:04Albert Farrugia: The Past, Present and Future of Blood Plasma Fractionation
-
Aug 18, 2025, 09:57Eugene Yang: When Should Prevention of Atherosclerosis Begin?
-
Aug 18, 2025, 09:34SIREN Study: Important Insights Hypertension and Low Vegetable Consumption Double Stroke Odds
-
Aug 18, 2025, 09:03Genetic Insights: FVIII A3 Variants and Inhibitor Risk
-
Aug 17, 2025, 11:34DAPT After PCI: Sex-Specific Strategies Unveiled
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Aug 17, 2025, 07:31Melissa Korn's story: Recognizing Pulmonary Embolism Symptoms Can Save Lives, NBCA
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
Aug 18, 2025, 11:04
Aug 18, 2025, 09:57
Aug 18, 2025, 09:45
Aug 18, 2025, 09:03
Aug 18, 2025, 08:48